Evaluating the effects of dapagliflozin on kidney function in advanced chronic kidney disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess whether dapagliflozin can slow the decline of kidney function and reduce the risk of death from cardiovascular or renal causes in adults with advanced chronic kidney disease (CKD), with or without type 2 diabetes. Participants will be randomly assigned to receive either dapagliflozin or a placebo, allowing researchers to compare the outcomes related to kidney and cardiovascular health. The study focuses on a high-risk population that has been largely excluded from previous major trials, addressing a significant gap in current treatment guidelines for patients with severe CKD.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients aged eighteen or older.
* Patients with advanced chronic kidney disease (i.e., eGFR \< 20 mL/min/1.73m2)not on dialysis

Exclusion Criteria:

* Autosomal dominant polycystic kidney disease (ADPKD).
* Type 1 diabetes mellitus
* Patients on SGLT2 inhibitors.
* History of ketoacidosis in the last 3 months.
* Known hypersensitivity to SGLT2 inhibitors.
* Known hepatic impairment.
* Pregnant or breastfeeding females.

Where it's running

• Ain Shams University Hospitals
  Cairo, Egypt Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CTAP101 extended-release capsules in kids with CKD and vitamin D insufficiency

  A daily bedtime dose of CTAP101 is being tested in children with CKD stages 3–4 and secondary hyperparathyroidism to see how the drug moves in the body, how it affects the body, and whether it is safe and tolerable.

  Recruiting Phase 2 OPKO Health, Inc. · Kansas City, Missouri and 4 other locations · NCT07494045

• Home-based exercise to boost fitness for people waiting for a kidney transplant

  This study tests whether a 12-week, home-based exercise program plus a wearable activity tracker helps adults on the kidney transplant waiting list increase daily activity and improve physical function.

  Recruiting University of Pennsylvania · Philadelphia, Pennsylvania · NCT07446296

• Improving decision-making for older adults with advanced kidney disease

  This study is testing a new way to help older adults with advanced kidney disease make better decisions about their treatment by improving communication with their doctors.

  Recruiting The University of Hong Kong · Hong Kong · NCT06799936

• BZLF1 peptide vaccine with QS-21 to prevent EBV-related cancers in patients awaiting organ transplants

  This early-phase trial tests a BZLF1-based vaccine (OSU-2131) with QS-21 to see if it is safe and can help prevent EBV infection and related cancers in healthy people and in patients waiting for a solid organ transplant.

  Recruiting Phase 1 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT06741072

• Telemonitoring platform for high-risk chronic kidney disease patients

  This study is testing if a new virtual care platform can help people with advanced kidney disease stay healthier and avoid trips to the emergency room or hospital.

  Recruiting at 5 sites University of Manitoba · Winnipeg, Manitoba and 4 other locations · NCT05726526

• Transplanting stem cells and kidneys from the same donor to prevent rejection

  This study is testing if giving patients stem cells and a kidney from the same donor can help prevent kidney rejection without needing lifelong medication to suppress their immune system.

  Recruiting Phase 1/2 Stanford University · Palo Alto, California · NCT05508009

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.